Deal Watch: AbbVie, arGEN-X To Explore Immuno-Oncology According To GARP

Also during a busy two-week stretch, AbbVie signs a partnership to co-develop drug conjugate products with CytomX, acquires privately held Stemcentrx, and agrees to a broad-based five-year cancer research collaboration with University of Chicago. Sanofi makes formal bid to acquire Medivation, which is rejected.